Pubblicazioni

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

2021 - ANNALS OF HEMATOLOGY

Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M.

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience

2020 - ANNALS OF HEMATOLOGY

Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

2019 - ANNALS OF HEMATOLOGY

Breccia, M.; Bartoletti, D.; Bonifacio, M.; Palumbo, G. A.; Polverelli, N.; Abruzzese, E.; Bergamaschi, M.; Tieghi, A.; Tiribelli, M.; Iurlo, A.; Cavazzini, F.; Sgherza, N.; Binotto, G.; Isidori, A.; D'Adda, M.; Crugnola, M.; Bosi, C.; Heidel, F.; Molica, M.; Scaffidi, L.; Cattaneo, D.; Latagliata, R.; Auteri, G.; Lemoli, R. M.; Fanin, R.; Russo, D.; Aversa, F.; Cuneo, A.; Semenzato, G.; Catani, L.; Cavo, M.; Vianelli, N.; Foa, R.; Palandri, F.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy

2018 - ANNALS OF HEMATOLOGY

Cicconi, L; Breccia, M; Franceschini, L; Latagliata, R; Molica, M; Divona, M; Diverio, D; Rizzo, M; Ottone, T; Iaccarino, L; Alfonso, V; Foa, R; Voso, Mt; Lo-Coco, F

Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience

2018 - ANNALS OF HEMATOLOGY

De Felice, Francesca; Grapulin, Lavinia; Pieroni, Alessandra; Salerno, Francesca; DâElia, Gianna Maria; Pulsoni, Alessandro; Musio, Daniela; Tombolini, Vincenzo